collaboration
Global Coalition for Adaptive Research Launches Adaptive Platform Trial for Ovarian Cancer
The nonprofit and partners are sponsoring a multi-arm trial to evaluate ovarian cancer therapies against standard-of-care treatments and collect biomarker data.
Nucleai, Jefferson Health Partner to Discover Biomarkers of Immunotherapy Response
Nucleai will use its ATOM platform to identify histological biomarkers, and Jefferson Health will test their ability to identify best responders to immunotherapy in the clinic.
MD Anderson, Snipr Biome Partner to Reduce Immunotherapy Toxicity With Microbiome CRISPR Approach
The partners will develop CRISPR-based therapies that alter patients' microbiome signatures in the hopes of improving their ability to tolerate combination immune checkpoint inhibitors.
Exact Sciences, NSABP Validating Ability of ctDNA Test to Detect MRD in Colorectal Cancer Patients
The study, called CORRECT-MRD II, is expected to enroll approximately 750 patients at 35 study sites in the US and Canada.
Cedars-Sinai, Tempus Partner on Molecular Database Initiative
The partners launched the Molecular Twin initiative to collect cancer patients' DNA, RNA, and protein information and use it to inform treatment and advance research.